OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer

Inclusion Criteria

• •1. Women over 18 years old;
• •2. Pathologically confirmed as stage I-IV primary epithelial ovarian malignant tumor;
• •3. ECOG \< 2;
• •4. The expected survival period exceeds 6 months;
• •5. CA125 ≤ 35 U/ml before initial treatment;
• •6. Undergo surgery and adjuvant chemotherapy;
• •7. The period between diagnosis and enrollment does not exceed 8 weeks;
• •8. Be willing to provide blood samples for OCS testing during the research process;
• •9. Sign the informed consent form.